Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest Expenses (2016 - 2025)

Amphastar Pharmaceuticals has reported Interest Expenses over the past 13 years, most recently at $6.6 million for Q4 2025.

  • Quarterly results put Interest Expenses at $6.6 million for Q4 2025, up 3.19% from a year ago — trailing twelve months through Dec 2025 was $25.5 million (down 16.02% YoY), and the annual figure for FY2025 was $25.5 million, down 16.02%.
  • Interest Expenses for Q4 2025 was $6.6 million at Amphastar Pharmaceuticals, up from $6.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for AMPH hit a ceiling of $13.7 million in Q3 2023 and a floor of $86000.0 in Q2 2021.
  • Median Interest Expenses over the past 5 years was $4.9 million (2023), compared with a mean of $4.3 million.
  • Biggest five-year swings in Interest Expenses: soared 2320.85% in 2023 and later plummeted 51.12% in 2024.
  • Amphastar Pharmaceuticals' Interest Expenses stood at $168000.0 in 2021, then surged by 214.29% to $528000.0 in 2022, then skyrocketed by 1690.91% to $9.5 million in 2023, then tumbled by 32.05% to $6.4 million in 2024, then increased by 3.19% to $6.6 million in 2025.
  • The last three reported values for Interest Expenses were $6.6 million (Q4 2025), $6.3 million (Q3 2025), and $6.3 million (Q2 2025) per Business Quant data.